Back

GLP-1 receptor agonists for anthracycline-associated cardiac outcomes: first meta-analytic evaluation in propensity-matched cohorts

30 August 2026 (14:54 - 15:06)
Organised by: Logo
Congress Presentation Part of: Predicting and preventing cancer therapy–related cardiac dysfunction: from artificial intelligence to cardiometabolic protection Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Anchit Chauhan

(India)

4 More presentations in this session

Presentation thumbnail
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of diastolic dysfunction in a cardio-oncology cohort
Mr J. Singh (US)
Abstract
Presentation thumbnail
Artificial intelligence–enabled electrocardiography as a pre-treatment predictor of chemotherapy-related cardiac dysfunction
Doctor M. Lee (Bucheon, KR)
Abstract
Presentation thumbnail
Healthcare utilization and costs in cancer therapy-related heart failure: a national inpatient sample analysis
Doctor L. Cruz (Santiago de los Caballeros, DO)
Abstract
Presentation thumbnail
Stratification of cancer-therapy related cardiac dysfunction: a validated prediction tool to identify low risk patients.
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract

Access the full session

Session thumbnail
Predicting and preventing cancer therapy–related cardiac dysfunction: from artificial intelligence to cardiometabolic protection

The Event

Event poster

ESC Congress 2026

30 August 2026 14:54 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1-ra and heart failure-related outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
23 May 2023
thumbnail
Congress Presentation
Monitoring of anthracycline-induced cardiotoxicity in the treatment of haematological malignancies, a local perspective
29 June 2021
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources